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ENVIRONMENTAL SCAN
Mallery C1, Ganachari D2, Smeeding L2, Fernandez J2, Lavallee D3, Siegel J4, Robinson S2,
Moon M1
1American Institutes for Research, Silver Spring, MD, USA, 2American Institutes for Research,
Washington, DC, USA, 3Center for Medical Technology Policy, Baltimore, MD, USA, 4Agency for
Healthcare Research and Quality (AHRQ), Rockville, MD, USA
OBJECTIVES: Involving stakeholders in research helps ensure that research is rele-
vant and responsive to stakeholder needswhile improving the quality of the research.
This researchwas conducted as part of AHRQ’s Community Forumprojectwhichwas
chargedwith identifyingemergingstrategiesandstateof theartmethods for engaging
stakeholders. METHODS: We developed a conceptual framework for stakeholder
engagement that informed this literature scan and assisted in organizing findings.
The scan included a search of peer-reviewed literature, using academic databases
as well as an Internet search of grey literature and Web sites. Our final review
included 23 peer-reviewed articles, 15 grey literature documents, and 43Web sites
related to stakeholder engagement. To supplement our scan, we conducted 11
interviews with individuals experienced in the field of stakeholder engagement.
Our technical experts also suggested organizations andWeb sites to explore in our
literature review. RESULTS: We identified many promising methods of involving
stakeholders in research. One example is using online collaborative platforms to en-
able interactions between an organization and its stakeholders through a virtual
space. These allowusers to share information,work together, andprovide feedback to
stakeholders about how their input is being used. Other examples include product
development challenges, utilizing existing online communities, and grassroots com-
munity organizing. Selected recommended practices fromour review include gaining
trust of stakeholders before involvement and maintaining throughout; selecting
stakeholders for whom the decision or research has important consequences; and
educating stakeholders on their roles, their responsibilities, and the topics being dis-
cussed.A limitation toourfindings is that there are limited evaluationdatameasuring
outcomeeffectiveness of thesemethods.CONCLUSIONS: Stakeholder involvement is
critical to health care research. This presentation will highlight selected effective and
creative approaches to stakeholder engagement.
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OBJECTIVES: To analyze the profile of care for sexually transmitted infections
(STIs) in health centers in border areas of Central America. METHODS: A cross-
sectional study in a sample of 3357 people receivedmedical care for some STIs in 13
health centers in border areas of Central America, during 2007-2010. Doctors were
trained and suppliedmedicines, condoms and HIV testing (basic package of health
care). The sample of users was characterized according to sociodemographic vari-
ables and the associated factors with the probability of receiving the basic package
of care for STIs were analyzed using additive probit regression models. RESULTS:
Of the total users, 66% had 25 to 59 years old, and 93% of users were women. The
most frequently diagnosed STI were Candidiasis, Bacterial Vaginosis, Trichomo-
niasis, Gonorrhea and Syphilis. 60% of prescriptions for these STIs were adhered to
the international recommendations. 53.1 % of users received onlymedicines, 5.8 %
received medicines plus HIV testing, 30.8 % received medicines plus condoms and
only 10% of them received the complete basic package. The likelihood of receiving
was lower in women. CONCLUSIONS: It is not enough to increase service delivery
capacity to change care practices. These are deeply rooted in the sociocultural
context related notions and cultural biases. Highlights gendered medical practices
that adversely affect the profile of care.
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OBJECTIVES: Pompe disease is a rare disease that affects between 5,000 and 10,000
people worldwide. It is an inheritedmetabolic myopathy caused by deficiency of acid
alpha-glucosidase (GAA) enzyme in lysosomal cells. The purpose of this study was to
review and compare recent developments in Pompe disease therapy.METHODS: Us-
ing PubMed and other Internet-based search engines, we reviewed Pompe disease
epidemiology and recent new drug development, and compared two newly-ap-
proved therapies in terms of their indications, efficacy, and safety profiles.
RESULTS: The incidence of Pompe disease varies among different populations,
ranging from 0.0032% in African Americans to 0.002% for the Chinese. There are
two forms of Pompedisease: infantile-onset and late-onset. The survival rate to age
one is about 25.7% for those with the infantile-onset disease. Two new drugs are
both enzyme replacement therapies (ERTs), including Myozyme® (alglucosidase
alfa, rhGAA) and Lumizyme® (alglucosidase alfa). They were approved as orphan
drugs by the U.S. Food and Drug Administration in 2006 and 2010, respectively.
Both are biologics that have beenmarketed around the world. While Myozyme® is
indicated for infantile-onset, Lumizyme® is for children 8 years old or older. Both
drugs improve the survival rate, but there remains a need to monitor risk of heart
and lung failure among those on treatment. CONCLUSIONS: Although ERT is an
approved effective treatment for Pompe disease, gene therapy is under develop-
ment in order to correct sequence coding gene for the deficient enzyme into cells.
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OBJECTIVES: To explore the data sources used in economic evaluations performed
on new drugs, and to propose an improved data infrastructure in order to deal with
future value-based decision making in health care policy in Japan.METHODS:We
systematically reviewed economic evaluation studies of the new drugswhichwere
launched in Japan betweenApril 2006 andMarch 2011, andwhich have been priced
by the cost calculation method, one of two types of pricing for new drugs in Japan.
The “Ichushi” and Pubmed databases were used to find the published articles.
RESULTS: A total of 198 drugs were priced under cost calculation methods in the
last 5 years in Japan. Fourteen published articles (9 drugs) were found: 5 CUAs and
10 CEAs (including one that was both CUA and CEA). In all studies, several data
from different sources were incorporated. Cost data were estimated by using stan-
dard treatment protocols and national price lists for drugs andmedical services, or
obtained from a limited number of claims data. Efficacy data were obtained from
RCTs or clinical trial data mostly conducted in Japan. In 4 out of the 5 CUAs, utility
data were used from other studies conducted on non-Japanese samples, and 2
CUAs did not consider transferability issues. Other data, such as epidemiological
data, were adopted from overseas as well as Japanese studies; usually mortality
rates were from Japanese statistics, while incident rates were from overseas.
CONCLUSIONS: In order to increase quality and efficiency to conduct economic
evaluations on new drugs, three steps need to be taken in the data environment:
increased accessibility to large cost databases such as the national claims data-
base; establish an epidemiological database; and collect and accumulate utility
data in Japanese samples.
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OBJECTIVES: Despite much research to understand patient nonadherence, clear
research-based evidence of how to reduce non-adherence remains elusive. This
paper describes two related studies conducted as part of the FP7 European Com-
mission funded Ascertaining Barriers to Compliance (ABC) project. We sought to
develop consensus-based policy solutions to address medicines adherence and
benchmark current implementation activity for those policy solutions.METHODS:
Delphi study: A 4-round Delphi study was conducted with 49 participants from 14
countries, representative of a range of stakeholder groups. Participants engaged in
the study remotely, anonymously and electronically. Participants responded to
open questions about the causes, consequences and solutions to medication non
adherence. Subsequent rounds refined responses, and sought ratings of the rela-
tive importance, operational and political feasibility of each potential solution to
medication nonadherence. Feedback of responses was provided to participants
after each round. A consensus meeting was held to discuss and further refine the
proposed policy solutions. National self-assessment study: An online survey and
follow-up telephone interview were conducted based on policy solutions resulting
from the consensus study. National medicines leads within the Ministries of
Health for the 27 European Union member states were invited to participate. Par-
ticipants rated the extent and appropriateness of implementation of each policy
solution in their country. RESULTS AND CONCLUSIONS: Twenty-five policy solu-
tions were prioritised based on composite scores for importance, operational and
political feasibility. Prioritised policy solutions focused on interventions for pa-
tients, training for healthcare professionals, and actions to support patient-clini-
cian partnership. Few solutions concerned actions by governments, health care
payers, or interventions at the system level. Implementation varied across nations.
Some European nations had not identified medication adherence as a priority and
tended to be concernedwith developingmore general clinical governance arrange-
ments. Some European nations had more systematic, co-ordinated approaches to
implementing policy solutions to address medication nonadherence.
PHP10
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OBJECTIVES: Medicines that are considered to be clinically effective but not cost-
effective by the Pharmaceutical Benefits Advisory Committee (PBAC) may be reim-
bursed in Australia through two pathways: by meeting the ‘rule of rescue’ (RoR)
criteria to be listed on the Pharmaceutical Benefits Scheme, or being included on
the life-saving drugs programme (LSDP). The criteria for the RoR and LSDP share
some similarities, but the LSDP criteria are less subjective andmore restrictive.We
sought to analyse and compare outcomes for submissions that were considered
under the RoR and LSDP from2008 to 2011.METHODS: Public SummaryDocuments
of PBAC recommendations for 2008-2011 were reviewed to identify submissions
that were considered for reimbursement citing the RoR or requested listing on the
LSDP. Outcomes of the applications were analysed and Payer interviews were un-
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dertaken to better understand the factors influencing the funding decisions.
RESULTS: During this period three submissions were considered under the RoR
criteria, two in 2008 and one in 2009. None of these were approved for listing on the
basis of the RoR, however two were accepted on the basis of high clinical need and
high but acceptable cost-effectiveness ratio. No submission has requested consid-
eration under the RoR, or been assessed under this criteria by the PBAC, since
November 2009. In comparison, from 2008-2011, 4 new applications and 5 re-sub-
missions requested listing on the LSDP and 3 of these were successful.
CONCLUSIONS: Despite stricter criteria for the LSDP than the RoR, applications to
the LSDP have had a better success rate. The RoR has not been used to justify a
listing on the PBS for at least four years, perhaps indicating that these criteria are
no longer favoured by the PBAC.
PHP11
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OBJECTIVES: In Brazil, the concepts of minimization cost are being applied in price
analyses of newpharmaceuticals since 2004,whenwas published the Resolution of
Brazilian Chamber of Economic Regulation of Pharmaceuticals (CMED) n° 2/2004.
The drugs are divided in two types: new drugs presentations and new molecules,
these are classified by two categories: I - New product with patent of molecule,
which has scientific evidences of benefits over the medications used on the same
treatment; II - New products which were not classified as category I. The prices
analyses of new drugs are classified by twomethods the lowest international price
and cost of treatment considering an existing medication traded in Brazil. The
category I take in the consideration the lowest international price and the category
II considering the cost of treatment and international price, the lowest of them. The
goal of this research is to evaluate the price regulation of new molecules over the
last eight years and all the consequences in terms of prices and a decrease of costs
for the society. METHODS: Only data of prices analyses assessed by Office of Eco-
nomic Assessment of New Technologies of Brazilian Health Surveillance Agency
(Anvisa), which supports the decisions of CMED, were evaluated. RESULTS: Ac-
cording to our statistics, 209 new molecules - category I and II - (over 563 presen-
tations) were analyzed. During the last eight years, the difference between the
price proposed by the laboratories and the price analyzed by Anvisa has been
reduced, as demonstrated bellow: Category I 21%; Category II 39%. CONCLUSIONS:
It suggests the prices are more in conformity of the resolution. In fact, the Resolu-
tion CMED n° 2/2004 brought rational price decrease and, in consequence, cost
decrease for the private and public sector, improving the efficiency of health care.
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OBJECTIVES: Shortages of antibiotics adversely impact health outcomes and
health care costs. We assessed the prevalence of shortages of systemic antibiotics
and evaluated the characteristics of the antibiotics in short supply as reported by
federal agencies and private health care providers in the US on June 1, 2011.
METHODS: Data were collected from the FDA, American Society of Health-System
Pharmacists (ASHP), and Brigham and Women’s Hospital (BWH) websites. The
units of analysis were active ingredient(s) and route of administration. The preva-
lence of shortageswas estimated as a percentage of the total number of products in
theUSmarket as of June 1, 2011.RESULTS:A total of 18 antibiotic active ingredients
with 20 routes of administration were in short supply as of June 1st, 2011. The
prevalence of shortages of systemic antibiotics varied from20.6% reported byASHP
to 3.1% reported by the FDA and BWH. Injectable antibiotics had the highest (28.3%)
rate of shortage followed by oral products (11.4%). Three shortageswere resolved as
of December 31, 2011. The average duration of shortage as of Dec-31-2011 was
589.2304.6 days. The average number of companies marketing the products in
short supply was 5.43.1, with 5 products having only 1 manufacturer. Generic
products were available for 95.0% of the drugs. The brand name product was dis-
continued for 55.0% of the drugs. The drugs in shortage had an average of 2.31.0
shortages from 2001 to 2011. Shortages resulting from discontinuation occurred
because of problems with manufacturing (35.0%), raw materials (15.0%), FDA reg-
ulatory issues (5.0%), and for unknown reasons (45.0%). CONCLUSIONS: Over one-
fourth of the injectable systemic antibiotics available in the United States were
reported in short supply. Problems with manufacturing and raw materials repre-
sented most of the reported causes of shortages. Additional research is needed to
assess the risk factors and causes of pharmaceutical shortages in theUnited States.
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OBJECTIVES: To estimate the impact of Medicare Part D on prescription and med-
ical utilization among Arizona’s senior dual eligible population. METHODS: This
study was a retrospective analysis of changes in pharmaceutical utilization and
physician visits among Arizona senior dual eligible (Medicaid and Medicare) ben-
eficiaries between the ages of 66 and 80 as of January 1, 2006 relative to a compar-
ison group (Medicaid beneficiaries between the ages of 50 and 62 as of January 1,
2006). Medical and pharmacy claims from the Medicaid program from January 1,
2005 to December 31, 2007 were used in this analysis. Differences between groups
with respect to over-the-counter (OTC) medications, benzodiazepines, total pre-
scription utilization, generic medication utilization, and physician visits were es-
timated using generalized estimating equations. RESULTS: The dual eligibles and
comparison group were similar in their level and trend of utilization of over-the-
counter (OTC) medications and benzodiazepines in the pre-Part D period. Follow-
ing implementation of Part D, therewas an immediate decline in utilization of both
OTCmedications and benzodiazepines in the dual eligibles relative to the compar-
ison group (p 0.001). An upward trend was observed for both groups during the
pre-Part D period for total prescription utilization and generic medication utiliza-
tion. After the implementation of Medicare Part D, utilization of these drug classes
was significantly lower among the dual eligibles relative to the comparison group
(p0.001). Trends in physician office visits were similar for the entire study period.
During the first month of Part D, however, the dual eligibles had a significantly
larger increase in physician visits over the previous month relative to the compar-
ison group (p0.001). CONCLUSIONS: This study suggests that medication use for
dual eligible Medicare beneficiaries was disrupted by the transition of outpatient
drug benefits from Medicaid to Medicare Part D.
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OBJECTIVES: Between $69 billion and $230 billion is spent on health care fraud
annually. Most health care fraud cases are initiated by private citizens (qui tam
relators), who receive up to 30% of recoveries. We reviewed recently concluded
Federal health care fraud activities and compared our findings to those reported
previously Kesselheim. METHODS: Data were from Taxpayers against Fraud and
Department of Justice websites (January 2006 to October 2010). Cases pursued un-
der the Federal False Claims Act (FCA), the most commonly employed law invoked
in these investigations, were identified. Information on allegations, recoveries, and
qui tam relator awards was abstracted. RESULTS: From 2006 to 2010, 116 Federal
health care FCA cases were identified, mainly involving improper billing (64%),
improper financial relationships (34%), and illegalmarketing (18%) concluded.Most
cases involved pharmaceuticalmanufacturers (27%), hospitals (20%), or health sys-
tems (15%). In comparison to cases without qui tam relators (39 cases, $1.9 billion in
recoveries), those with qui tam relators (77 cases, $12.4 billion in recoveries) had
greatermean per-case recoveries ($380million versus $110million for pharmaceu-
tical cases; $42 million versus $25 million for hospital cases; and $170 million
versus $34 million for health systems cases). Qui tam relators received $1.1 billion.
Among qui tam relator cases closed since 2006 versus 1996-2005, cases involving
hospitals and health systems decreased 84% and 30%, respectively (per-case recov-
eries increased 14-fold and 2.7-fold, respectively); and pharmaceutical manufac-
turers’ cases tripled (to 34) (per-case recoveries doubled to $380 million).
CONCLUSIONS: Since 2006, 116 health care FCA cases were settled, accounting for
$14.3 billion in recoveries. Qui tam relators continue to play a dominant role, ac-
counting for the majority of 70% of the cases and financial recoveries. New inves-
tigation approaches including field audits, task force investigations, and predictive
modeling investigations augment qui tam relator led investigations.
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OBJECTIVES: High prices of orphan medicines are a cause for concern as they put
pressure on pharmaceutical budgets and may negatively influence patient access
to pharmacotherapy. While repurposing of drugs is an attractive strategy to over-
come the logistical and financial burden of the first phases of medicine develop-
ment, we argue that repurposed medicines for rare indications, for which effec-
tiveness evidence has already been published, do not warrant high prices.
METHODS:We identified 16 examples of repurposedmedicines for rare indications
for which effectiveness evidence was published prior to the application for orphan
designation and compared Belgian hospital prices between the common disease
and the rare indication of the same medicine. RESULTS: In the majority of cases
(n 13), the pharmaceutical form of the medicine was identical for the common
and for the rare indication. Medicine prices (per defined daily dose) for the rare
indication were nearly the same as for the common disease for cladribine and
tadalafil, and ranged from a two-fold difference (e.g. aztreonam, sildenafil) to a
200-fold difference for histamine. Three medicines had a different pharmaceu-
tical form for the rare indication: medicines for the rare indication were at least
56 times more expensive than for the common disease. Hospital prices per dose
for the rare indication were at least 23 times higher than for the common
disease. CONCLUSIONS: This study suggests that the majority of these selected
repurposed medicines for rare indications are over-priced. This pricing practice is
not justified and adds to the budget impact of treating rare diseases. There is a need
to individually assess repurposed medicines taking into account the costs of re-
search and development and the costs of market access that can be attributed to
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